参考文献/References:
[1]Peschel RE.Prostate implant therapy:iodine125 versus palladium103.Cancer J，2005,11:383-384.
[2]Ellis WJ.Prostate brachytherapy.Cancer Met Rev,2002,21:125-129.
[3]Nag S,Beyer D,Friedl J,et al.American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.Int J Radiat Oncol Biol Phys,1999,44:789-799.
[4]Merrick GS,Butler WM,Wallner KE.et al.Dysuria after permanent prostate brachytherapy.Int J Radiat Oncol Biol Phys，2003，55:979-985.
[5]王俊杰.放射性粒子近距离治疗前列腺癌:临床篇.国外医学·放射医学核医学分册，2002，26:101-104.
[6]Peschel RE,Colberg JW,Chen Z,et al.Iodine125 versus palladium103 implants for prostate cancer: clinical outcomes and complications.Cancer J，2004,10:170-174.
[7]Ragde H,Korb L,Elgamal A,et al.Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed followup.Cancer,2000,89:135-141.
[8]瞿颖,蔡文,李萌,等.30例放射性粒子种植治疗前列腺癌患者的护理.中华护理杂志,2005,40:178-179.
[9]姜玉良，王俊杰，甄鹏，等.放射性103Pd粒子组织间植入治疗恶性肿瘤.中国微创外科杂志,2007,7:130-133.
[10]Sharkey J,Cantor A,Solc Z,et al.103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer:a 12year experience from a single group practice.Brachytherapy，2005,4:34-44.
[11]Ellis RJ,Vertocnik A,Sodee B,et al.Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.Brachytherapy，2003,2:215-222.
[12]Wallner K,Merrick G,True L,et al.I125 versus Pd103 for lowrisk prostate cancer:morbidity outcomes from a prospective randomized multicenter trial.Cancer J，2002，8:67-73.
[13]Grimm P,Blasko J,Sylvester J,et al.10year biochemical (prostatespecific antigen) control of prostate cancer with (125)I brachytherapy.Int J Radiat Oncol Biol Phys,2001,51:31-40.
[14]陈萍，魏献忠，刘衍民，等.103Pd种子源植入治疗肿瘤近期疗效观察.中华核医学杂志,2003,23:152-153.
[15]Aileen B,Anthony V,Bridget A,et al.Patient and treatment factors associated with complications after prostate brachytherapy.J Clin Oncol,2006,24:5298-5304.
[16]Sherertz T,Wallner K,Merrick G,et al.Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.Brachytherapy，2004,3:130-135.
[17]Gejerman G,Mullokandov E,Saini AJ,et al.The effects of edema on urethral dose following palladium103 prostate brachytherapy.Med Dosim，2002,27:221-225.
[18]Barker J Jr,Wallner K,Merrick G.Gross hematuria after prostate brachytherapy.Urology，2003,61:408-411.
[19]Merrick GS,Butler WM,Wallner KE,et al.Brachytherapy related dysuria.BJU Int，2005，95:597-602.
[20]Incrocci L,Slob AK,Levendag PC.Sexual (dys) function after radiotherapy for cancer:a review.Int J Radiat Oncol Biol Phys,2002,52:681-693.
[21]Merrick GS,Butler WM,Dorsey AT,et al.Seed fixity in the prostate/periprostatic region following brachytherapy.Int Radiat Oncol Biol Phys,2000,46:215-220.
[22]Meigooni AS,Awan SB,Rachabatthula V,et al.Treatment planning consideration for prostateimplants with the new linear RadioCoil 103Pd brachytherapy source.J Appl Clin Med Phys，2005,6:23-36.
[23]The International Commission on Radiological Protection.Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources.A report of ICRP Publication 98.Ann ICRP，2005,35:3-50.